

AMENDMENT

In the claims:

1. (Currently Amended) A pharmaceutical product, ~~consisting essentially of~~ comprising:

a) a therapeutically-effective amount of a pharmaceutical;

b) at least one compressible material;

c) at least one lubricating material; and

d) wherein said product is in the form of a caplet having a diameter from about 1 millimeter to about 7 millimeters and a length from about 1 millimeter to about 7 millimeters.

2. (Previously presented) The pharmaceutical product of claim 1 wherein said pharmaceutical is selected from the group consisting of: antitussives, antihistamines, decongestants, alkaloids, mineral supplements, laxatives, antacids, ion exchange resins, anti-cholesterolemics, antiarrhythmics, antipyretics, analgesics, appetite suppressants, expectorants, anti-anxiety agents, anti-ulcer agents, anti-inflammatory substances, coronary dilators, cerebral dilators, peripheral vasodilators, anti-infectives, psychotropics, antimanics, stimulants, gastrointestinal agents, sedatives, anti-diarrheal preparations, anti-anginal drugs, vasodialators, anti-hypertensive drugs, vasoconstrictors, migraine

treatments, antibiotics, tranquilizers, anti-psychotics, antitumor drugs, anticoagulants, antithrombotic drugs, hypontics, anti-emetics, anti-nausants, anti-convulsants, neuromuscular drugs, hyper- and hypoglycemic spasmodics, uterine relaxants, mineral and nutritional additives, antiobesity drugs, anabolic drugs, erythropoetic drugs, antiashmatics, cough suppressants, mucolytics, anti-uricemic drugs and mixtures thereof.

3. (Previously presented) The pharmaceutical product of claim 2, wherein the said pharmaceutical is a psychotropic.

4. (Previously presented) The pharmaceutical product of claim 3, wherein said psychotropic is a anti-anxiety therapeutic.

5. (Previously presented) The pharmaceutical product of claim 3, wherein said psychotropic is an insomnia therapeutic.

6. (Previously presented) The pharmaceutical product of claim 3, wherein said psychotropic is an antidepressant.

7. (Previously presented) The pharmaceutical product of claim 6, wherein said antidepressant is selected from the group consisting of Fluoxetine HCl, Paroxetine HCl, Sertraline HCl, and

Venlafaxine HCl, Amitriptyline, Nortriptyline, Imipramine, Desipramine, Doxepin, Trimipramine, Clomipramine, Protriptyline, Amoxapine, Maprotiline, Phenelzine, Tranylcypromine, Fluvoxamine, Venlafaxine, Trazodone, Nefazodone, Mirtazapine, Bupropion, or mixtures thereof.

8. (Withdrawn) The encapsulated product of claim 7, wherein said pharmaceutical is Fluoxetine HCl.

9. (Withdrawn) The encapsulated product of claim 2, wherein said pharmaceutical is a gastrointestinal therapeutic.

10. (Withdrawn) The encapsulated product of claim 9, wherein said gastrointestinal therapeutic is a ulcer therapeutic.

11. (Withdrawn) The encapsulated product of claim 10, wherein said ulcer therapeutic is selected from the group consisting of Omeprazole, Lansoprazole, Ranitidine HCl, Famotidine, Nizatidine, Teprenone, Cimetidine, Rabeprazole sodium, Sulpiride, or mixtures thereof.

12. (Withdrawn) The encapsulated product of claim 11, wherein said ulcer therapeutic is Omeprazole.

13. (Withdrawn) The encapsulated product of claim 9, wherein said gastrointestinal therapeutic is a anti-emetic.

14. (Withdrawn) The encapsulated product of claim 13, wherein said anti-emetic is selected from the group consisting of Ondansetron HCl, Granisetron HCl, dimenhydrinate, Tropisetron, Dolasetron mesylate, Cisapride, Sulfasalazine, Balsalazide, Infliximab, or mixtures thereof.

15. (Withdrawn) The encapsulated product of claim 14, wherein said anti-emetic is dimenhydrinate.

16. (Withdrawn) The encapsulated product of claim 9, wherein said gastrointestinal therapeutic is a anti-diarrheal therapeutic.

17. (Withdrawn) The encapsulated product of claim 16, wherein said anti-diarrheal therapeutic is selected from the group consisting of Loperamide HCl, diphenoxylate, codeine phosphate, camphorated opium tincture, or mixtures thereof.

18. (Withdrawn) The encapsulated product of claim 17, wherein said anti-diarrheal therapeutic is Loperamide HCl

19. (Withdrawn) The encapsulated product of claim 2, wherein

said pharmaceutical is a migraine therapeutic.

20. (Withdrawn) The encapsulated product of claim 19, wherein said migraine therapeutic is selected from the group consisting of sumatriptan succinate, amitriptyline, methysergide, propranolol, valproate, verapamil, dihydroergotamine, ergotamine, metoclopramide, naratriptan, prochlorperazine, rizatriptan benzoate, zolmitriptan, eletriptan, acetaminophen, aspirin, NSAID's, opioids, or mixtures thereof.

21. (Withdrawn) The encapsulated product of claim 20, wherein said migraine therapeutic is sumatriptan succinate.

22. (Withdrawn) The encapsulated product of claim 2, wherein said pharmaceutical is a therapeutic for the treatment of hypertension.

23. (Withdrawn) The encapsulated product of claim 22, wherein said therapeutic is selected from the group consisting of nifedipine, amlodipine besylate, losartan potassium, lisinopril, felodipine, benazepril HCl, ramipril, irbesartan, verapamil HCl, bisoprolol fumarate and hydrochlorothiazide, amlodipine and

benazepril HCl, clonidine, candesartan, cilexetil, diltiazem, nicardipine, imidapril, trandolapril, eprosartan mesylate, nilvadipine, verapamil HCl, temocapril, prazosin HCl, isradipine, cilazapril, celiprolol, bisoprolol, betazolol HCl, ramipril, nisoldipine, lisinopril, trandolapril, and nisoldipine.

24. (Withdrawn) The encapsulated product of claim 23, wherein said therapeutic is nifedipine.